Activated Stellate Cell Paracrine HGF Exacerbated Pancreatic Cancer Cell Ferroptosis Resistance

Figure 4

Activated PSCs promoted ferroptosis resistance in pancreatic cancer in vivo. (a–g) C57BL/6 mice were injected subcutaneously with Panc02 (Panc02 groups, cells/mouse) or Panc02+PSCs (Co-Panc02 groups, ). They were divided into Panc02 groups (treated with DMSO), Co-Panc02 groups (DMSO), Panc02+H (HGF, 50 ng/i.h., every two days), Panc02+E (Piperazine Erastin, 30 mg/kg/i.h., every two days), Co-Panc02+E (Piperazine Erastin, 30 mg/kg/i.h., every two days), and Panc02+H+E (HGF, 50 ng/i.h., Piperazine Erastin, 30 mg/kg/i.h., every two days). (a) Representative photographs of isolated tumor tissues in each treatment group at day 14. (b) Tumor volume was detected every two days. (c) The body weight of mice in each treatment group was measured every two days. (d, e)D-E. The GSH (d) and MDA (e) levels in isolated tumors were assayed at day 14 after different treatments. (f) Western blot analysis of protein expression levels of ferroptosis-related indicators (SLC7A11 and GPX4) of isolated tumor tissues in each treatment group. (g) Immunohistochemistry analysis of the expression of c-MET in isolated tumor tissues. (h) The expression of c-MET in PDAC patients and normal pancreatic tissues (T: tumor; N: normal) and the correlation between the expression of c-MET and the survival of PDAC patients were analyzed with the GEPIA database. (i) Analysis of the TCGA and GEPIA databases for the correlation c-MET mRNA expression level with the ferroptosis-related indicators (NRF2, SLC7A11, and GPX4). The TCGA database result was presented by heat map: . PE: Piperazine Erastin. Experiments were repeated three times, and the data were expressed as the . , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)